

Achaogen Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 15-Dec-2014

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)

ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 10

 Phase 3 Clinical..... 11

 Discovery..... 20

[Return to Table of Contents](#)

Achaogen Inc

COMPANY OVERVIEW

Company Name	Achaogen Inc
Parent Company Name	Achaogen Inc
Website	http://www.achaogen.com/
Country	US
Number of Drugs in Active Development	3
Number of Inactive Drugs	3
Number of Patents as Owner	41
Number of Patents as Third Party	1
Number of Deals	12
Key Indications	Gram negative bacterium infection, Bacterial infection, Pseudomonas aeruginosa infection, Enterobacteriaceae infection, Escherichia coli infection, Multidrug resistant infection, Bacterial pneumonia, Bacterial urinary tract infection, Pyelonephritis, Sepsis
Key Target-based Actions	LpxC inhibitor, SOS gene inhibitor, Penicillin binding protein inhibitor
Key Technologies	Small molecule therapeutic, Antibiotic, Oral formulation, Systemic formulation unspecified, Infusion, Intravenous formulation, Drug combination, Crystalline form, Formulation preservation

COMPANY PROFILE

SUMMARY

Achaogen Inc is a biotechnology company, established by August 2004, focused on the development of small molecule compounds to combat multi-drug resistance in bacteria. It takes products to the early clinical development stage at which point it seeks worldwide external resources for late-stage clinical work. The company is pursuing several unique strategies to combat these pathogens, including the development of drugs (achaogens) against the induced mutation process that is upregulated in bacteria during antibiotic exposure and that leads to the introduction of mutations that may confer antibiotic resistance.

COMPANY LOCATION

Achaogen Inc is headquartered in San Francisco, CA where it has a state-of-the-art research facility.

LICENSING AGREEMENTS

In January 2008, ChemDiv entered into an agreement with Achaogen to discover and develop antibacterial compounds. Financial terms were not disclosed.

In June 2007, Albany Molecular Research (AMRI) agreed to screen its natural product libraries against Achaogen's therapeutic targets for antibiotic resistance. AMRI would also provide other discovery and follow-up services, and will receive upfront fees, milestones and royalties.

In August 2004, Achaogen entered into a small-molecule research and discovery collaboration with NeoGenesis Pharmaceuticals Inc. NeoGenesis would use its drug discovery technologies, including its ALIS (Automated Ligand Identification System) platform, NeoMorph compound libraries and lead optimization technologies to discover drug candidates against selected targets.

EARLY R&D

By April 2010, the company was investigating 'neoglycosides', next generation aminoglycosides, which have demonstrated broad-spectrum activity against multi-drug resistant gram-negative bacterial infections.

FINANCIAL

[Return to Table of Contents](#)



In January 2014, Achaogen filed a registration statement with the US SEC for a proposed initial public offering of its common stock shares. In March 2014, the company priced an IPO of 6 million shares of common stock at \$12.00 per share and granted the underwriters a 30-day option to buy up to an additional 900,000 shares to cover any over-allotments. The shares were expected to begin trading on the NASDAQ Global Market under the ticker symbol "AKAO" on March 12, 2014. At that time, the offering was expected to close on March 17, 2014. Later that month, the offering was closed and the company raised gross proceeds of \$82.8 million and net proceeds of approximately \$73.9 million, from the IPO of 6.9 million shares, including full exercise of underwriters overallotment option. The shares had begun trading on the NASDAQ under the ticker symbol "AKAO".

In April 2010, the company raised \$56 million from the closing of a series C financing round.

In October 2006, Achaogen was awarded a 4-year, \$24.7 million contract from the Defense Threat Reduction Agency for the development of therapies for anthrax and other bioterror agents.


Earlier in October 2006, Achaogen raised over \$26 million from a series B financing round.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

Drugs by Indication Table

Indication	Active	Inactive	Total
Infectious disease	3	3	6
Respiratory disease	1	0	1
Inflammatory disease	1	0	1
Genitourinary disease	1	0	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Discovery	2
No Development Reported	3

[Return to Table of Contents](#)

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Discovery/Design	0	0	3	0	3
Technology - Other Proprietary	0	0	1	0	1
Patent - Exclusive Rights	0	0	1	0	1
Drug - Funding	2	0	1	0	5
Drug - Development/Commercialization License	0	0	1	0	1
Technology - Target Validation	0	0	1	0	1

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Infectious disease	1	5
Respiratory disease	1	2
Inflammatory disease	0	1
Genitourinary disease	0	1

Trials by Phase

Phase	Ongoing	All
Phase 3	1	3
Phase 2	0	1
Phase 1	0	7
Phase not specified	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)



PATENTS *

Indication	As Owner	As Third Party	Total
Gastrointestinal disease	5	0	5
Genitourinary disease	1	0	1
Neoplasm	2	1	3
Respiratory disease	9	0	9
Infectious disease	36	1	37
Toxicity and intoxication	1	0	1

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

plazomicin

plazomicin SNAPSHOT

Drug Name	plazomicin
Key Synonyms	plazomicin sulfate;plazomicin
Originator Company	Ibis Therapeutics
Active Companies	Achaogen Inc
Inactive Companies	Ibis Therapeutics
Highest Status	Phase 3 Clinical
Active Indications	Bacterial urinary tract infection;Bacterial pneumonia;Sepsis;Pyelonephritis;Enterobacteriaceae infection
Target-based Actions	
Other Actions	Antibacterial multidrug resistance inhibitor;Antibacterial;Aminoglycoside antibiotic
Technologies	Intravenous formulation;Antibiotic;Infusion;Small molecule therapeutic
Last Change Date	11-Nov-2014

plazomicin DEVELOPMENT PROFILE

SUMMARY

Under license from Isis and its Ibis Therapeutics division, Achaogen is developing plazomicin (ACHN-490), the lead in a series of next-generation aminoglycoside antibiotics called neoglycosides, for the potential iv treatment of multi-drug resistant gram-negative bacterial infections,.

In February 2014, a phase III study was initiated in patients with bloodstream infection or nosocomial pneumonia due to carbapenem-resistant enterobacteriaceae (CRE). In March 2010, a phase II trial began in patients with complicated urinary tract infection (cUTI) or acute pyelonephritis.

In March 2012, the company was seeking to outlicense the drug.

Achaogen is also investigating a second series of expanded-spectrum neoglycosides for gram-negative bacterial infections.

plazomicin DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
---------	------------	---------	--------------------	------


[Return to Table of Contents](#)


Company	Indication	Country	Development Status	Date
Achaogen Inc	Bacterial pneumonia	Asia	Phase 3 Clinical	21-Feb-2014
Achaogen Inc	Bacterial pneumonia	Europe	Phase 3 Clinical	21-Feb-2014
Achaogen Inc	Bacterial pneumonia	South America	Phase 3 Clinical	21-Feb-2014
Achaogen Inc	Bacterial pneumonia	US	Phase 3 Clinical	21-Feb-2014
Achaogen Inc	Enterobacteriaceae infection	Asia	Phase 3 Clinical	21-Feb-2014
Achaogen Inc	Enterobacteriaceae infection	Europe	Phase 3 Clinical	21-Feb-2014
Achaogen Inc	Enterobacteriaceae infection	South America	Phase 3 Clinical	21-Feb-2014
Achaogen Inc	Enterobacteriaceae infection	US	Phase 3 Clinical	21-Feb-2014
Achaogen Inc	Sepsis	Asia	Phase 3 Clinical	21-Feb-2014
Achaogen Inc	Sepsis	Europe	Phase 3 Clinical	21-Feb-2014
Achaogen Inc	Sepsis	South America	Phase 3 Clinical	21-Feb-2014
Achaogen Inc	Sepsis	US	Phase 3 Clinical	21-Feb-2014
Achaogen Inc	Bacterial urinary tract infection	US	Phase 2 Clinical	31-Mar-2010
Achaogen Inc	Pyelonephritis	US	Phase 2 Clinical	31-Mar-2010
Ibis Therapeutics	Bacterial infection	US	Discontinued	31-Jan-2006

plazomicin CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
1154757-24-0	2
	
Name	Type
plazomicin	INN; USAN
ACHN-490	Research Code

[Return to Table of Contents](#)

CAS Registry Number:	Confidence Level:
1380078-95-4	2
	
Name	Type
plazomicin sulfate	USAN

CAS Registry Number:	Confidence Level:
640749-39-9	3
	

[Return to Table of Contents](#)




plazomicin DRUG NAMES

Names	Type
IBIS-346377	Research Code
plazomicin sulfate	USAN
aminoglycosides (bacterial infection), Achaogen	
IBIS-345539	Research Code
RNA-targeted antibiotics, Ibis Therapeutics	
neoglycosides (Gram-negative bacterial infection), Achaogen)	
IBIS-363012	Research Code
RNA-targeted antibiotics, Achaogen	
ACHN-490	Research Code
plazomicin	USAN, INN

plazomicin SALES AND FORECASTS

CHARTS

[Return to Table of Contents](#)



[Return to Table of Contents](#)

COMMENTARY

CONSENSUS SALES INFORMATION

Consensus forecast data for Achaogen are presented.

REGIONAL DEVELOPMENT AND MARKETING RIGHTS

In January 2006, Isis licensed exclusive worldwide rights for its Ibis aminoglycosides program to Achaogen [647677].

plazomicin CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Enterobacteriaceae infection											
0	0	1	2	0	0	0	0	0	0	1	2
Pneumonia											
0	0	1	2	0	0	0	0	0	0	1	2
Gram negative bacterium infection											
0	0	0	1	0	0	0	1	0	0	0	2
Pyelonephritis											
0	0	0	0	0	1	0	0	0	0	0	1
Bacterial infection											
0	0	0	0	0	0	0	1	0	0	0	1
Urinary tract infection											
0	0	0	0	0	1	0	0	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	1	3	0	1	0	4	0	1	1	9

Phase Definitions

Phase 3 Clinical

[Return to Table of Contents](#)

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

plazomicin DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Achaogen Inc	1	1	3	0	5
US Government	0	0	1	1	2
Wellcome Trust	1	0	0	0	1
Isis Pharmaceuticals Inc	1	0	0	0	1
Ark Diagnostics	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	2	1	3
Technology - Other Proprietary	1	0	1
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Achaogen Inc	5	0	5
US Government	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
New use	2
Product	1
Formulation	1
Component of Combination	1

[Return to Table of Contents](#)

expanded-spectrum neoglycosides (Gram-negative bacterial infection), Achaogen

expanded-spectrum neoglycosides (Gram-negative bacterial infection), Achaogen SNAPSHOT

Drug Name	expanded-spectrum neoglycosides (Gram-negative bacterial infection), Achaogen
Key Synonyms	
Originator Company	Achaogen Inc
Active Companies	Achaogen Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Gram negative bacterium infection
Target-based Actions	
Other Actions	Aminoglycoside antibiotic;Antibacterial multidrug resistance inhibitor;RNA modulator
Technologies	Antibiotic;Small molecule therapeutic
Last Change Date	10-Apr-2012

expanded-spectrum neoglycosides (Gram-negative bacterial infection), Achaogen DEVELOPMENT PROFILE

SUMMARY

Achaogen is investigating a series of next-generation, expanded-spectrum aminoglycoside antibiotics, termed neoglycosides, presumed to include ACHN-978, for the potential treatment of multidrug-resistant, Gram-negative bacterial infections including *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Yersinia pestis* and *Francisella tularensis* infections,. In January 2009, lead optimization was underway and at that time, the company was investigating different formulations including inhaled, intramuscular and topical. In July 2011, the program was listed as being in preclinical development. In March 2012, the company was seeking to outlicense ACHN-978.

Achaogen is also investigating the neoglycoside compound ACHN-490 for Gram-negative bacterial infections.

expanded-spectrum neoglycosides (Gram-negative bacterial infection), Achaogen DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Achaogen Inc	Gram negative bacterium infection	US	Discovery	08-Jan-2009

[Return to Table of Contents](#)




expanded-spectrum neoglycosides (Gram-negative bacterial infection), Achaogen DRUG NAMES

Names	Type
expanded-spectrum neoglycosides (Gram-negative bacterial infection), Achaogen	
expanded-spectrum aminoglycosides (Gram-negative bacterial infection), Achaogen	
ACHN-978	Research Code

expanded-spectrum neoglycosides (Gram-negative bacterial infection), Achaogen DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Achaogen Inc	0	1	1	0	2
Wellcome Trust	1	0	0	0	1
US Government	0	0	0	1	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	1	1	2

LpxC membrane biosynthesis inhibitors (multidrug-resistant bacterial infection), Achaogen

LpxC membrane biosynthesis inhibitors (multidrug-resistant bacterial infection), Achaogen SNAPSHOT

Drug Name	LpxC membrane biosynthesis inhibitors (multidrug-resistant bacterial infection), Achaogen
Key Synonyms	
Originator Company	Achaogen Inc
Active Companies	Achaogen Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Gram negative bacterium infection;Multidrug resistant infection
Target-based Actions	LpxC inhibitor
Other Actions	Antibacterial multidrug resistance inhibitor
Technologies	Systemic formulation unspecified;Antibiotic;Small molecule therapeutic
Last Change Date	18-Nov-2013

LpxC membrane biosynthesis inhibitors (multidrug-resistant bacterial infection), Achaogen DEVELOPMENT PROFILE

SUMMARY

Achaogen is investigating a program of membrane biosynthesis inhibitors targeting LpxC, for the potential treatment of multidrug-resistant (MDR) gram-negative bacterial infections (including *Yersinia pestis* infection) such as *Pseudomonas aeruginosa* (*P aeruginosa*), enterobacteriaceae and *Yersinia pestis*,. In October 2013, the program was in preclinical development.

The company was previously developing ACHN-975 (structure shown) for the potential treatment of multidrug-resistant (MDR) gram-negative bacterial infections (including *Yersinia pestis* infection) such as *Pseudomonas aeruginosa* (*P aeruginosa*), enterobacteriaceae and *Yersinia pestis*,. In May 2012, a phase I study was initiated in healthy volunteers. In June 2013, the trial was completed ; however, by October 2013, development of ACHN-975 had presumed to be discontinued.

LpxC membrane biosynthesis inhibitors (multidrug-resistant bacterial infection), Achaogen DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS


Company	Indication	Country	Development Status	Date
Achaogen Inc	Gram negative bacterium infection	US	Discovery	08-Jan-2009
Achaogen Inc	Multidrug resistant infection	US	Discovery	08-Jan-2009

LpxC membrane biosynthesis inhibitors (multidrug-resistant bacterial infection), Achaogen CHEMICAL STRUCTURES

[Return to Table of Contents](#)



CAS Registry Number:	Confidence Level:
	4
	
Name	Type
ACHN-975	Research Code

CAS Registry Number:	Confidence Level:
	4
	
Name	Type
LpxCi-4	Research Code

LpxC membrane biosynthesis inhibitors (multidrug-resistant bacterial infection), Achaogen DRUG NAMES

Names	Type
LpxCi-4	Research Code
LpxC membrane biosynthesis inhibitors (multidrug-resistant bacterial infection), Achaogen	
ACHN-975	Research Code

LpxC membrane biosynthesis inhibitors (multidrug-resistant bacterial infection), Achaogen CLINICAL TRIALS

[Return to Table of Contents](#)


Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	3	0	0	0	3

LpxC membrane biosynthesis inhibitors (multidrug-resistant bacterial infection), Achaogen DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Achaogen Inc	1	1	1	0	3
US Government	0	0	1	1	2
University of Washington	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	1	1	2
Patent - Exclusive Rights	1	0	1

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

